Vaksigrip

Vaksigrip – the vaccine for prevention of flu creating development of the specific immunity (remaining from 6 to 12 months) to epidemic urgent influenza strains And yes Century.

Form of release and structure

Dosage form of Vaksigrip – suspension for intramuscular and hypodermic introduction, slightly whitish, poorly opalescent liquid. Is issued on:

• 0,5 ml of a vaccine in the syringe, 1 syringe in the closed strip packaging, in a cardboard pack 1 packaging;
• 0,5 ml of a vaccine in an ampoule, 10 ampoules in a blister strip packaging, in a cardboard pack on 2 packagings (20 ampoules);
• 1 dose of a vaccine (0,25 ml) in the syringe, 1 syringe in the closed strip packaging, in a cardboard pack 1 packaging;
• 5 ml a bottle (bottle), 1 piece in a pack cardboard.

1 dose (0,5/0,25 ml) includes active agents – hemagglutinin and a neuraminidase of the following virus strains:

• And (H1 N1) – 15/7,5 mkg of HECTARE;
• And (H3 N2) – 15/7,5 mkg of HECTARE;
• B – 15/7,5 mkg of HECTARE.

Excipients: buffered solution (sodium chloride, hydrophosphate sodium a dihydrate, potassium chloride, potassium dihydrophosphate, water for injections) – to 0,5 ml.

Indications to use

Vaksigrip apply to prevention of flu at adults and children 6 months are more senior. Vaccination is allowed to be carried out at the following diseases / states:

• Diabetes mellitus;
• Chronic renal failure;
• Diseases of cardiovascular system and respiratory organs;
• Immunodeficiency (including HIV infection);
• Malignant diseases of blood;
• The accompanying therapy by cytostatics, immunodepressants, high doses of glucocorticosteroids;
• Radiation therapy.

Vaksigrip can apply elderly people (65 years are more senior) and pregnant women in case of high risk of infection with flu.

Contraindications

• Acute feverish condition or exacerbation of chronic diseases (vaccination can be carried out after remission or recovery);
• Allergic reactions to the previous drug use;
• Not heavy SARS (vaccination can be carried out after normalization of body temperature);
• Hypersensitivity to drug components, including to aminoglycosides and chicken protein.

The doctor individually taking into account risk of a disease and possible complications of an influenzal infection has to make the decision on vaccination of pregnant women. It is the safest to carry out vaccination in the II-III trimesters of pregnancy.

Vaksigrip's use during feeding by a breast perhaps as drug has no toxic and teratogenic effect on a fruit.

Route of administration and dosage

Vaksigrip it is possible to enter:

• Subcutaneously deeply in an upper third of an outside surface of a shoulder;
• Intramusculary in a deltoid muscle;
• In the anterolateral surface of a hip – to children of younger age.

To children from 6 months to 3 years enter once 0,25 ml of drug; the flu which is not vaccinated, and also not hurting earlier, the vaccine is entered twice with an interval of 4 weeks.

To adults and children of 3 years Vaksigrip enter once 0,5 ml.

The patient with an immunodeficiency perhaps double administration of drug on 0,25 ml with an interval of 4 weeks.

Side effects

• Often – perspiration, fatigue, a headache, an indisposition, a hyperthermia, a shiver, morbidity in joints and muscles, neuralgia (tranzitorno, in 1-2 days disappear);
• Seldom – paresthesias, thrombocytopenia, neuritis, encephalomyelitis, spasms, a syndrome to Giyena-Barra (unambiguous connection with vaccination is not established);
• Very seldom – allergic reactions up to shock, a vasculitis with a tranzitorny renal failure.

From local reactions are most probable: a hyperemia, consolidation, morbidity and hypostasis in an injection site, ecchymomas.

Special instructions

Vaccination is carried out annually to the autumn and winter period. Its carrying out is possible at the beginning of epidemic rise in incidence of flu.

Intravenous administration of Vaksigrip is not allowed.

At not heavy SARS and acute intestinal diseases vaccination can be carried out after normalization of body temperature.

In day of an inoculation of patients the doctor (paramedic) has to examine. Vaccination is not carried out at body temperature above 37 °C.

After Vaksigrip's use at an enzyme immunoassay false positive results of serological tests are possible that is caused by IgM development.

In offices of vaccination there have to be medicines of antishock treatment (Epinephrinum, glucocorticosteroids, etc.).

Vaksigrip may contain trace amounts of gentamycin.

Vaccination does not influence speed of psychomotor reaction and ability to concentration of attention.

After immunization the patient within half an hour has to be under observation of the medic.

The procedure of vaccination and opening of ampoules are held at strict observance of rules of antiseptics and an asepsis. In the opened ampoule drug is not subject to storage.

The drug with the broken marking or integrity of ampoules stored with disturbances of requirements with the changed physical properties (transparency, color) and expired is not suitable for use.

Medicinal interaction

Vaksigrip it is possible to apply along with other inactivated vaccines, at the same time it is necessary to consider contraindications to each of them (the drugs should be administered different syringes in different body parts).

Immunodepressants and glucocorticosteroids lower an immune response on administration of drug.

Terms and storage conditions

To store in protected from light, the place, unavailable to children, at a temperature of 2-8 °C. Not to freeze.

Period of validity – 12 months.